Alzinova starts ALZ-101 Phase II and launches ~$5.5M rights issue
Alzinova began Phase II operational start-up for ALZ-101 in early Alzheimer’s, targeting ~120 patients, with first patient expected around late 2026/early 2027. The company also launched a rights issue of approximately $5.5M to fund initiation and CMC.
Alzinova has begun the Phase II operational start-up for ALZ-101 in early Alzheimer’s, with the trial targeting about 120 patients. The company said the first patient is expected around late 2026 or early 2027. 5M to fund the trial initiation and CMC.